Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PTC Therapeutics (PTCT)

PTC Therapeutics sells Evrysdi royalty to Royalty Pharma for $240 million upfront

Mixed Impact 4 of 5 financing Written later

PTC Therapeutics sold its retained interest in its Evrysdi royalty stream to Royalty Pharma Investments 2019 ICAV on December 29, 2025, for $240.0 million in upfront cash. The company also may receive three additional $20.0 million payments, each tied to royalty payments exceeding set thresholds in 2027, 2028 and 2029, and it no longer owns any part of the royalty.

Key points

  • Upfront cash consideration of $240.0 million paid to PTC Therapeutics on December 29, 2025
  • Three potential $20.0 million payments, conditioned on Assigned Royalty Payments above $347.0 million (2027), $363.0 million (2028) and $379.0 million (2029)
  • Retained interest sold was 9.5111% of the Royalty before the 2020 Assigned Royalty Cap is met and 16.6666% after; PTC now owns 0% of the Royalty

The filing

CompanyPTC Therapeutics (PTCT)
Form8-K, current report
Filed with the SECDec 29, 2025, 4:05 PM ET
Accession number0001104659-25-124837

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 29, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.